$ARBE

Arbe Appoints Assaf Pereg, CPA, as Chief Financial Officer

Arbe Robotics Ltd. (Nasdaq: ARBE, TASE: ARBE) appointed Assaf Pereg, CPA, as incoming Chief Financial Officer effective Aug. 30, 2026. He succeeds Karine Pinto-Flomenboim. Arbe said Pereg has about two decades of finance leadership, most recently as SVP Finance at Ibex Medical Analytics, and previously held finance roles at Nano Dimension and others.

Original reporting
Published Aug 6, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Arbe Appoints Assaf Pereg, CPA, as Chief Financial Officer — source image
Decision brief

The 30-second read

$ARBENeutralLow
01

Why it matters

The CFO appointment may influence how the company communicates financial discipline and execution progress, but the release does not include guidance, financial results, or new commercial commitments.

02

Market read

This is primarily a corporate governance and execution-signal item, with no new financial metrics or orders disclosed.

03

What to watch

The market may react more to any future CFO commentary on margins, cash burn, and order timing than to the appointment itself.

Relevance 4/10Novelty 4/10Timing: effective Aug. 30, 2026 CFO start date

Background

Arbe is transitioning from development toward scaled production and expanding radar technology into markets beyond automotive.

Company-level read

Ticker impact

$ARBENeutralMedium confidence
Context

Arbe appointed Assaf Pereg as incoming CFO effective Aug. 30, 2026, replacing Karine Pinto-Flomenboim as the company moves into scaled production.

Expected impact

Likely limited near-term impact unless investors view the hire as improving execution toward scaled production and commercial orders.

Evidence & confidence

The article is a personnel appointment with no new numbers, contracts, or guidance; the only trading-relevant element is potential signaling for the next growth phase.

Market effects

Could modestly affect investor sentiment around radar/automotive sensing execution risk, but no sector-wide policy or demand datapoint is provided.

No direct new Israel-specific macro or regulatory trigger beyond generic risk language.

Limited global read-through because the release does not disclose new programs, orders, or partnerships.

Counterpoint

Investors may discount the hire as routine, focusing instead on upcoming milestones for scaled production and customer program wins that are not disclosed here.

Key entities

  • Arbe Robotics Ltd.

    Nasdaq-listed ultra-high-resolution radar solutions provider that announced an incoming CFO appointment.

  • Assaf Pereg, CPA

    Incoming CFO effective Aug. 30, 2026, with prior finance leadership roles across technology companies.

  • Karine Pinto-Flomenboim

    Outgoing CFO who will depart the company.

  • Ram Machness

    CEO who commented on the hire and the company’s scaled production and market expansion phase.

Related articles

$ARBEMedAI 8/10

Arbe Announces Second Quarter 2026 Financial Results

Arbe Robotics Ltd. (NASDAQ: ARBE) reported Q2 2026 results for the quarter ended June 30, 2026. Revenues rose to $0.7 million from $0.3 million a year earlier, with operating expenses of $9.8 million and net loss of $9.1 million. Cash was about $41.9 million. Full-year 2026 outlook: revenue $4-$6 million and adjusted EBITDA loss $28-$31 million.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.

$AMZNMed

Amazon is discussing selling $8 billion worth of Nvidia chips to investors and leasing them back.

Amazon is considering a deal to sell $8B of Nvidia Grace Blackwell chips to an SPV, then lease them back. The chips are for AI systems in Amazon's data centers. Investors may finance the SPV, with Amazon potentially offering a 10% stake. The arrangement aims to separate ownership from usage, reducing Amazon's capital expenditure. Nvidia and Amazon have not commented. According to the Financial Times, the deal is not finalized.